Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals

SRRKBullishCorporate Developmentsnews

High materiality9/10

Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

Jan 15, 2025, 2:43 PM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The positive outlook on apitegromab and an Overweight rating may drive SRRK growth.

AI summary

What happened, with direct paths to the underlying reporting

CEO Jay Backstrom discussed apitegromab for spinal muscular atrophy at J.P. Morgan. Company plans U.S. and European marketing applications by Q1 2025. Apitegromab projected to generate over $2 billion in global revenue. JP Morgan maintains an Overweight rating on Scholar Rock, citing strong SAPPHIRE results. Details from the phase 2 EMBRAZE trial expected in Q2 2025.

CEO Jay Backstrom discussed apitegromab for spinal muscular atrophy at J.P. Morgan.
Company plans U.S. and European marketing applications by Q1 2025.
Apitegromab projected to generate over $2 billion in global revenue.
JP Morgan maintains an Overweight rating on Scholar Rock, citing strong SAPPHIRE results.
Details from the phase 2 EMBRAZE trial expected in Q2 2025.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth

Scholar Rock advances apitegromab path with alternate fill-finish and PMDA alignment

EU decision on SRRK SMA therapy delayed as FDA facility classification awaits

US FDA declines to approve Scholar Rock's muscle weakness drug

Scholar Rock's drug helps preserve lean mass in mid-stage trial